Latest Amylyx Pharmaceuticals News & Updates

See the latest news and media coverage for Amylyx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amylyx Pharmaceuticals (Amylyx)

Biopharmaceutical company developing novel therapies

amylyx.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 150–200

Last updated Today

Latest news about Amylyx Pharmaceuticals (Amylyx)

In short: Amylyx progressed its clinical pipeline and financial position throughout 2025 and early 2026 despite settling an investor lawsuit for $6.5 million.

Company announcements

May 15 Amylyx

Amylyx publishes positive HELIOS trial results in Wolfram syndrome

Week 24 and 48 results show improved pancreatic function and visual acuity stabilization, with favorable safety.

May 7 Amylyx

Amylyx reports Q1 2026 financial results

R&D expenses rise to $27.6M, net loss $41.3M. LUCIDITY trial enrollment complete, topline data expected Q3 2026. Cash runway into 2028.

May 5 Amylyx

Amylyx announces U.S. Expanded Access Program for avexitide

The program provides access to eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Avexitide is in Phase 3 LUCIDITY trial with data expected Q3 2026.

March 24 Amylyx

Amylyx completes enrollment in Phase 3 LUCIDITY trial

The trial enrolled 78 participants for avexitide in post-bariatric hypoglycemia. Topline data expected in Q3 2026.

Media coverage

Yesterday Yahoo Finance

Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best Middle East and Africa stocks to buy according to hedge funds. On April 29, Teva...

May 15 GuruFocus

Amylyx (AMLX) Releases Promising Results from HELIOS Trial

On May 15, 2026, Amylyx Pharmaceuticals AMLX announced the publication of Week 24 and Week 48 findings from the Phase 2 open-label HELIOS clinical trial...

May 14 MSN

Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus

3 small-cap biotechs with potential breakthroughs in 2024 Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for...

May 7 MSN

Amylyx targets LUCIDITY top line data next quarter while launching expanded access for up to 250 PBH patients

Q1 2026 Management View “The first quarter of 2026 was marked by execution across our pipeline,” and “we remain on track for a top line...

Never miss news about Amylyx

Track Amylyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Amylyx competitors & trending companies

Browse news for competitors to Amylyx and other trending companies.